Latest Insider Positions


Williamson Thomas P. is listed as an insider in the following companies: ENTL / Entellus Medical, Inc. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Peers of Williamson Thomas P. include the following: BAKEWELL JOHN K, BOIANO MARGARET A, BURNHAM JONELLE R, Baltzell Joshua J, Christian Martha J., ESSEX WOODLANDS HEALTH VENTURES FUND VIII LP, ESSEX WOODLANDS HEALTH VENTURES FUND VIII-A LP, ESSEX WOODLANDS HEALTH VENTURES FUND VIII-B LP, Essex Woodlands Health Ventures VIII, L.L.C., Essex Woodlands Health Ventures VIII, L.P., Farley Brian E, GRIFFIN THOMAS E, Gonzales Donald A., INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P., INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P., INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P., KOGL JEFF L, MENSINK KEVIN L, MOMTAZEE JAMES C, McCormick Shawn, Milne David Bruce, Moen Brent, NEELS GUIDO J, PAIDOSH STEPHEN R, PETERSON KAREN E, PETRICK TIMOTHY B, Rohlen Douglas, Rosenthal Michael Harry, SUREK JAMES D, SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P., SV LIFE SCIENCES FUND IV, L.P., SVLSF IV, LLC, WHITE ROBERT S., . Peers are determined by cross-linking the filings of Williamson Thomas P. with insider filings of others at the same companies.

Click the link icon to see the full transaction history.

Latest
Tran Date
Security Code Shares Post Shares Percent
Change
Share
Price
Tran
Value
Post
Value
Percent
Change
2018-01-08 ENTL / Entellus Medical VP, Commercial Operations S -1,481 44,986 -3.19 24.12 -35,722 1,085,062 -3.29
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related News Stories

Why Stryker Will Likely Continue Delivering Strong Growth

2018-02-19 seekingalpha
The company's stock price has faltered some recently, but is still up significantly over the past 12 months. (12-0)

Stryker Producing Excellent Results, But Expectations Are High

2018-01-31 seekingalpha
Stryker delivered another great quarter of revenue growth, with strong results in Ortho, MedSurg, and Neuro. (17-0)

Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings?

2018-01-23 zacks
Stryker Corporation’s (SYK - Free Report) fourth-quarter 2017 results are scheduled for release on Jan 30, 2018, after the market closes. In the said quarter, the company is expected to witness year-over-year revenue growth in all other business segments apart from Orthopedics, Medsurg and Neurotechnology and Spine. (85-0)

Entellus (ENTL) Nears 52-Week High: What's Driving It?

2018-01-03 zacks
On Dec 29, 2017, Entellus Medical Inc.’s (ENTL - Free Report) shares reached a high of $25.58, closing the session nominally lower at $24.39. The company’s shares have returned 26.5% over the last year, higher than the S&P 500 index’s gain of 18.3%. Also, shares have outperformed the industry’s gain of 23% over the same time frame. The stock has a market cap of $619.14 million. (35-0)

Deals of the day- Mergers and acquisitions

2017-12-07 reuters
(Adds ArcelorMittal, Kiwi.com, Uniper, Royal KPN, Esaote, Sears, Stryker, British Airways, Nordic Capital, Potash Corp of Saskatchewan, Dialog Semiconductor, BASF, AT&T, Honeywell; updates GVC Holdings) (210-0)

UPDATE 1-Stryker beefs up ENT business with $662 mln Entellus buy

2017-12-07 reuters
(Reuters) - Medical device maker Stryker Corp (SYK.N) said on Thursday it would buy Entellus Medical Inc (ENTL.O) for $662 million, adding heft to its ear, nose and throat (ENT) business. (7-0)

Entellus Medical to be acquired by Stryker for $24 a share in cash - MarketWatch

2017-12-07 marketwatch
Entellus Medical Inc. ENTL, -1.54% said Thursday it has reached a deal to be acquired by Stryker Corp. SYK, -0.18% for $24 a share in cash, in a deal with an equity value of about $662 million. Entellus is a leader in technology for ear, nose and throat ailments, including sinusitis, nasal airway obstruction and Eustachian tube dysfunction. The company's board has approved the deal, which must now be approved by shareholders. (7-0)

BRIEF-Anthem Inc issues positive coverage decision for balloon sinus dilation

2017-11-13 reuters
* Entellus Medical - Anthem Inc now covers balloon sinus dilation for treatment of chronic and recurrent acute sinusitis​ Source text for Eikon: Further company coverage: (43-0)

Entellus Medical's (ENTL) CEO Bob White on Q3 2017 Results - Earnings Call Transcript

2017-11-01 seekingalpha
Welcome to Entellus Medical's 2017 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this conference call is being recorded today, November 1, 2017. (1-0)

BRIEF-Entellus Medical reports Q3 loss per share $0.13

2017-11-01 reuters
* Entellus Medical Inc - ‍Entellus recorded a special income tax benefit related to Spirox acquisition, totaling $14.9 million during q3 of 2017​ (1-0)